Pfizer Inc (PFE) was up 0.62% to $40.34 while its German partner for Covid-vaccine BioNTech SE (BNTX) rose 1.11% to $120.00 on Friday. The biotechnology company on Thursday revealed that it had decreased the number of doses of Covid-19 vaccine that it will be able to manufacture by the end of 2020. The U.S. biotech company cites problems in the supply chain of used raw materials. In recent weeks, the group has stated that it plans to produce 50 million doses this year, down from the 100 million doses previously anticipated. The group has, however, stated its aim to manufacture more than one billion doses of its vaccine by 2021.
Other vaccine player Moderna Inc (MRNA) was down -3.01 to $152.52 on Friday. The company said Thursday that during the first quarter of 2021 it would be able to supply between 100 million and 125 million doses of its experimental Covid-19 vaccine worldwide. 85 to 100 million doses in the United States and 25 million doses abroad will be available. By 2021, Moderna plans to be capable of delivering between 500 million and 1 billion doses.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
AstraZeneca Plc (AZN) closed the Friday trading session with a rise of 1.82 at $53.74. In news about AstraZeneca and Oxford this time, Reuters reported that the two partners have provided contradictory accounts about how they found the most successful dose for their Covid-19 vaccine candidate. AstraZeneca’s research manager told Reuters ten days ago, at the time of the release of the preliminary findings that half a dose was mistakenly given to some of the participants for the first injection, which eventually turned out to be a stroke of luck.
On Monday, an Oxford University scientist told Reuters that the half-dose vaccine had been purposely administered after consultation. “There was some misunderstandings that when we gave it, we didn’t realize we were giving half a dose,” that’s really not true. The half-dose subgroup had 90 percent efficacy.
